Showing 1 - 10 of 28,594
public expenditure, limiting financial exposure of patients, improving access to pharmaceuticals, and stimulating competition …
Persistent link: https://www.econbiz.de/10010224844
Persistent link: https://www.econbiz.de/10012506948
Persistent link: https://www.econbiz.de/10013431125
Persistent link: https://www.econbiz.de/10012197768
Persistent link: https://www.econbiz.de/10011708133
In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South. Governments in both countries may limit prices...
Persistent link: https://www.econbiz.de/10011986314
Persistent link: https://www.econbiz.de/10012242700
Persistent link: https://www.econbiz.de/10013208383
This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with a special focus on abuse of industrial property rights and related exclusionary and exploitative effects. The paper analyzes the case law of Brazilian Administrative Council for...
Persistent link: https://www.econbiz.de/10013365665
This paper examines the optimal content regulation of DTCA by comparing two forms of DTCA-product-specific and category-specific-and identifies a key tradeoff which underlies this policy debate. Our analysis suggests that the optimal form of DTCA depends crucially on the cost effectiveness of...
Persistent link: https://www.econbiz.de/10013329470